Targeted & controlled bone healing
02 Oct 19
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs

Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs

Schlieren (Zurich), Switzerland, October 2, 2019 – Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, announced today that it will host a Key Opinion Leader (KOL) luncheon on showcasing MagnetOs, its commercial stage advanced  bone graft on Wednesday, October 9 at the Widder Hotel in Zurich, Switzerland.

 

The KOL event will feature a presentation by KOL John Sutcliffe MBChB FRCS(Ed) FRCS(SN), from the London Spine Clinic, who will discuss the scientific and clinical rationale of MagnetOs, the overall treatment landscape in both Europe and the United States, as well as the potential of Kuros’ innovative portfolio in bone regeneration.

 

Kuros’ CEO Joost de Bruijn will give an investor presentation highlighting the Company’s progress to date and upcoming milestones. Details as to how Kuros’ commercial strategy will elevate MagnetOs to a leader within category will be unveiled.

 

John Sutcliffe is Triage Consultant Spinal Neurosurgeon & Lead Clinician, London Spine Clinic, having trained in Edinburgh and qualifying in 1983. He was appointed as a consultant neurosurgeon in 1993 and has since concentrated exclusively in the management of patients with spinal disorders. He pioneered the concept of the multi-disciplinary team approach to spinal disorders, setting up the London Spine Clinic in 1997, the first hospital of its kind in the UK at the time. He resigned from the NHS in 2000 but remains an Emeritus Consultant at Barts' and the London NHS Trust. As training director in the NHS and at the London Spine Clinic and London Clinic Hospital, Mr. Sutcliffe has trained many young spinal surgeons in his 25 years as a consultant.

 

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.  A live webcast and replay will be accessible via the link here.



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
02 Oct 19
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs

Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs

Schlieren (Zurich), Switzerland, October 2, 2019 – Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, announced today that it will host a Key Opinion Leader (KOL) luncheon on showcasing MagnetOs, its commercial stage advanced  bone graft on Wednesday, October 9 at the Widder Hotel in Zurich, Switzerland.

 

The KOL event will feature a presentation by KOL John Sutcliffe MBChB FRCS(Ed) FRCS(SN), from the London Spine Clinic, who will discuss the scientific and clinical rationale of MagnetOs, the overall treatment landscape in both Europe and the United States, as well as the potential of Kuros’ innovative portfolio in bone regeneration.

 

Kuros’ CEO Joost de Bruijn will give an investor presentation highlighting the Company’s progress to date and upcoming milestones. Details as to how Kuros’ commercial strategy will elevate MagnetOs to a leader within category will be unveiled.

 

John Sutcliffe is Triage Consultant Spinal Neurosurgeon & Lead Clinician, London Spine Clinic, having trained in Edinburgh and qualifying in 1983. He was appointed as a consultant neurosurgeon in 1993 and has since concentrated exclusively in the management of patients with spinal disorders. He pioneered the concept of the multi-disciplinary team approach to spinal disorders, setting up the London Spine Clinic in 1997, the first hospital of its kind in the UK at the time. He resigned from the NHS in 2000 but remains an Emeritus Consultant at Barts' and the London NHS Trust. As training director in the NHS and at the London Spine Clinic and London Clinic Hospital, Mr. Sutcliffe has trained many young spinal surgeons in his 25 years as a consultant.

 

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.  A live webcast and replay will be accessible via the link here.